Author

Amber Cipriani

Observed names: Amber B. Cipriani, Amber Britton Cipriani, Amber E. Cipriani, Cipriani, Amber

Institutions: University of North Carolina at Chapel Hill, University of North Carolina Health Care

Observed institutions: University of North Carolina at Chapel Hill, University of North Carolina Health Care, University of North Carolina Hospitals, University of North Carolina System

ORCID: 0000-0003-3596-0581

Observed ORCID: 0000-0003-3596-0581

OpenAlex ID: A5014109040

Multisite evaluation of institutional processes and implementation determinants for pharmacogenetic testing to guide antidepressant therapy

2021 · Sony Tuteja, Ramzi G. Salloum, et al. · Clinical and Translational Science · 34

PDF

Integrating Pharmacogenomics into the Broader Construct of Genomic Medicine: Efforts by the ClinGen Pharmacogenomics Working Group (PGxWG)

2025 · Li Gong, Clarissa J Klein, et al. · Clinical Chemistry · 19

PDF

Mapping lesion-specific response and progression dynamics and inter-organ variability in metastatic colorectal cancer

2023 · Jiawei Zhou, Amber Cipriani, et al. · Nature Communications · 19

PDF

Best–worst scaling methodology to evaluate constructs of the Consolidated Framework for Implementation Research: application to the implementation of pharmacogenetic testing for antidepressant therapy

2022 · Ramzi G. Salloum, Jeffrey R. Bishop, et al. · Implementation Science Communications · 12

PDF

Chemotherapy‐associated cardiomyopathy: Mechanisms of toxicity and cardioprotective strategies

2021 · Justin A. Veeder, Lauren N. Hothem, et al. · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · 9

RYK Gene Expression Associated with Drug Response Variation of Temozolomide and Clinical Outcomes in Glioma Patients

2023 · Ricardo D. Gonzalez, George W. Small, et al. · Pharmaceuticals · 5

PDF

North Carolina’s Multi-Institutional Pharmacogenomics Efforts with the North Carolina Precision Health Collaborative

2021 · Jai N Patel, Deepak Voora, et al. · Pharmacogenomics · 3

Intracranial Activity of Sotorasib in KRAS G12C -Mutated Recurrent Glioblastoma

2025 · Katherine P. Morgan, Allison Carroll, et al. · JCO Precision Oncology · 1

Pharmacogenomic Prescribing Opportunities in Percutaneous Coronary Intervention and Bone Marrow Transplant Patients

2022 · Lindsay Ratner, Jing ‘Daisy’ Zhu, et al. · Pharmacogenomics · 1

Denosumab for First-Line Treatment of Hypercalcemia Associated with Malignancy: Retrospective Analysis

2021 · Amber Cipriani, PharmD, et al. · 1

Integrating ctDNA-based ESR1 m monitoring into first-line care for ER+, HER2− advanced breast cancer: a consensus workflow

2026 · Yara Abdou, Amber Cipriani, et al. · The Oncologist

PROGRESS: Implementation of a novel hybrid decentralized clinical trial to support precision oncology uptake at academic and community oncology practices in North Carolina.

2026 · Meghan McGonagle, Stephanie Drotts, et al. · Journal of Clinical Oncology

Association of immune checkpoint inhibitor administration timing with toxicity and survival in uterine cancer: A real-world analysis.

2026 · Meghan McGonagle, Sara Jubas, et al. · Journal of Clinical Oncology

PDF

Implementation of an academic precision oncology service in a community setting.

2025 · Junlone Moy, Jaime Richardson, et al. · Journal of Clinical Oncology

Efficacy of immunotherapy retreatment in patients with non-small cell lung cancer receiving consolidative durvalumab.

2024 · Allison Baker Carroll, Lindsay Renee Kohler, et al. · Journal of Clinical Oncology

Abstract 3789: Mapping lesion specific response and relapse patterns in metastatic colorectal cancer patients

2022 · Jiawei Zhou, Quefeng Li, et al. · Cancer Research

Works count: 22

Citation count: 104

H-index: 5

I10-index: 4